Navigation Links
Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
Date:12/1/2008

MSI-1436 and two subjects in each dosing group will receive placebo. The multiple ascending dose protocol has an adaptive design permitting the enrollment of additional subjects in each cohort. Data from the study is expected in the first half of 2009.

MSI-1436 is also being evaluated in preclinical studies using a once-weekly subcutaneously administered formulation which Genaera expects to utilize in Phase 2 clinical trials in the second half of 2009.

About Trodusquemine (MSI-1436)

Trodusquemine is a centrally and peripherally-acting appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme central to controlling the function of both the leptin and insulin pathways. By inhibiting PTP1B, MSI-1436 is expected to decrease appetite and normalize blood sugar. Trodusquemine has produced consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to reverse co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.

About Genaera

Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in Phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in Phase 2 clinical testing in asthma. For further information, please see our website at www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations a
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
11. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015  Research ... addition of the "An Introduction to the ... 2015)" conference to their offering. ... the European medical device legislation. It will explain ... involvement of Notified Bodies, how to choose one ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ) has ... Legislation (London, UK - November 16-17, 2015)" conference ... EU modules concerning Pharmacovigilance are a major departure in ... Europe . The intention of the course ... examine how they overlap and fit together and what ...
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... Companies" to their offering. This ... clinical specialty, aimed at improving patient care by ... adjust the dose of drugs for improving outcome. ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2
... , , HOUSTON, Nov. 16 Cyberonics, Inc. ... to its tax position. , In its fiscal second quarter ... GAAP tax benefit of approximately $40 million resulting from the ... losses. The recognition of this tax benefit follows from ...
... , , LOS ANGELES, Nov. ... a 40-year-old Indian rhinoceros, has successfully completed treatment for ... to deliver electronic, x-ray based therapy directly to cancer ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20091116/SF11909 ) , Randa was ...
Cached Medicine Technology:Cyberonics Provides Update on Tax Position 2Cyberonics Provides Update on Tax Position 3Cyberonics Provides Update on Tax Position 4L.A. Zoo Announces Successful Cancer Treatment of Rhinoceros With Electronic Brachytherapy 2L.A. Zoo Announces Successful Cancer Treatment of Rhinoceros With Electronic Brachytherapy 3
(Date:9/3/2015)... York, New York (PRWEB) , ... September 03, 2015 , ... ... of the Division of Trauma, Burns, Critical and Acute Care at NewYork-Presbyterian/Weill Cornell Medical ... College. , Dr. Winchell is a nationally renowned expert in care for the critically ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... DiabetesSisters is pleased to announce the additional of Carol Wysham, MD, to their ... board members Diana Karczmarczyk, Donna Rice, David Warren, Matt Stella, Tricia Cedotal, Andrea ...
(Date:9/3/2015)... ... ... A scar is an unavoidable result of incision or injury to the skin. Unsightly as ... itself. The appearance of a scar is dependent on many factors – the size and ... scars fade to near invisibility on their own over a period of months,” says ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... a top review from Clinicians Report of Provo, Utah. The Clinicians Report is ... a selected group of dentists located throughout the U.S. Whiter Image's In-Office whitening ...
(Date:9/3/2015)... ... 2015 , ... James Earl Jones will be hosting an upcoming VOICES IN ... Jones will introduce a segment that discusses why it is important for the workplace ... be fostered in any working environment. , Employers are out billions of dollars year ...
Breaking Medicine News(10 mins):Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2
... relative of the highly pathogenic avian influenza virus (H5N1) ... including// chlorination, ultraviolet (UV) radiation and bacterial digesters. The ... case of the pathways by which the influenza could ... related virus, called H5N2, to see whether a hypothetical ...
... Although it’s our most vital organ, surprisingly little ... That makes it harder to uncover what’s gone ... other brain-associated disorders, and ultimately, it often leaves ... such as Alzheimer’s and Parkinson’s disease, schizophrenia, attention ...
... management of the health service has been revealed by the ... nurses, measly pay rises// and strikes. ,A copy ... reveals that 37000 posts are in danger as the Government ... 2.7 per cent cut in the workforce. ,NHS ...
... circumcision procedure could reduce 50% of the HIV infection rate ... number of Ugandan men seeking it.// , ... reports, out of which nearly half were adults. Less than ... Institutes of Health found that new HIV infections among circumcised ...
... international homeopathy conference is taking place in this Taj ... and eight countries.// ,The four-day meet, which ... AIDS and "other difficult subjects which have proved a ... secretary, told IANS., ,The slogan of the conference ...
... surgical team was led by Dr. Christopher Moir at Minnesota's ... North Dakota// (ND) and now they are on the challenging ... Madysen Fitterer, the twin girls born on Aug. 8 to ... the chest - were both doing very well following the ...
Cached Medicine News:Health News:Avian Flu Unlikely to Spread Through Water Systems 2Health News:Researchers Looking for Genes That Control the Brain 2Health News:A Secret Dossier Predicts Major Changes At NHS, England 2
... A new Transnasal Lacrimal Stent has been ... B. Becker, M.D., the Transnasal Lacrimal Stent addressed ... and other forms of endoscopic DCR. Brought in ... relatively large diameter. Because there is no need ...
...
... electrophysiology system is the Espion. This is an ... wide variety of stimulators for different types of ... ,The Espion system was designed from the ... standard clinical visual function tests, ERG, VEP, PERG, ...
... SIREMOBIL Iso-C3D is based on SIREMOBIL ... the industry. In the intra-operative 3D-Mode, the ... the motorized 190 orbital movement. This allows ... in greater precision during the procedure. This ...
Medicine Products: